Market Place
Sourcing Support
Altimmune Presents Hearing Loss Gene Therapy Long-Term Data
23 Apr 2026 //
FIRSTWORD PHARMA
Altimmune Unveils 2025 Financial Results And Business Updates
05 Mar 2026 //
GLOBENEWSWIRE
Altimmune Completes $75M Common Stock Offering
29 Jan 2026 //
GLOBENEWSWIRE
Altimmune Granted FDA Breakthrough Status For Pemvidutide In MASH
05 Jan 2026 //
GLOBENEWSWIRE
Altimmune eyes phase 3 MASH trial as weight loss deepens
19 Dec 2025 //
GLOBENEWSWIRE
Altimmune To Join Piper Sandler Healthcare Conference
26 Nov 2025 //
GLOBENEWSWIRE
Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb
13 Nov 2025 //
BIOSPACE
Altimmune Announces Publication of IMPACT Phase 2b Trial Data
11 Nov 2025 //
GLOBENEWSWIRE
Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b
07 Nov 2025 //
GLOBENEWSWIRE
Altimmune To Present Phase 2B Pemvidutide Data In MASH At AASLD
20 Oct 2025 //
GLOBENEWSWIRE
Altimmune Names Christophe Arbet-Engels, M.d., Phd CMO
29 Sep 2025 //
GLOBENEWSWIRE
Altimmune’s Pemvidutide Gets FDA Fast Track in Alcohol Disorder
19 Aug 2025 //
GLOBENEWSWIRE
Altimmune`s Q2 2025 Financial Results and Business Update
12 Aug 2025 //
GLOBENEWSWIRE
Altimmune Reports Positive Pemvidutide Ph2b Results
26 Jun 2025 //
GLOBENEWSWIRE
Altimmune to Reveal Pemvidutide Ph2b Results on June 26
25 Jun 2025 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Investor Conferences
14 May 2025 //
GLOBENEWSWIRE
Altimmune Predicts MASH Resolution with Pemvidutide at EASL
08 May 2025 //
GLOBENEWSWIRE
Altimmune to Report Q1 2025 Results and Business Update on May 13
06 May 2025 //
GLOBENEWSWIRE
Altimmune to Present at EASL Liver Congress 2025
01 May 2025 //
GLOBENEWSWIRE
Altimmune to test obesity drug for alcohol use disorder & conditions
14 Mar 2025 //
REUTERS
Altimmune to Participate in Guggenheim SMID Cap Biotech Conference
29 Jan 2025 //
GLOBENEWSWIRE
Altimmune Added to Nasdaq Biotechnology Index
19 Dec 2024 //
GLOBENEWSWIRE
Altimmune Presents Pemvidutide Data in MASLD at The Liver Meeting®
15 Nov 2024 //
GLOBENEWSWIRE
Altimmune To Present New Data On Lipidomic Profile With Pemvidutide
15 Oct 2024 //
GLOBENEWSWIRE
Altimmune Completes Enrollment In IMPACT Trial For Pemvidutide
30 Sep 2024 //
GLOBENEWSWIRE
Altimmune: EASL 2024 Data Supports Pemvidutide In MASH
05 Jun 2024 //
GLOBENEWSWIRE
Altimmune`s Pemvidutide Data At EASL Liver Congress 2024
29 May 2024 //
GLOBENEWSWIRE
Altimmune Announces Presentation of Pemvidutide Clinical Data
02 Jan 2024 //
GLOBENEWSWIRE
Altimmune’s pemvidutide meets weight-loss expectations in study
01 Dec 2023 //
GLOBENEWSWIRE
Altimmune Granted Fast Track Designation by FDA for Pemvidutide
26 Oct 2023 //
GLOBENEWSWIRE
Altimmune to Present New Data on the Anti-Inflammatory Properties of Pemvidutide
25 Oct 2023 //
GLOBENEWSWIRE
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data
26 Sep 2023 //
GLOBENEWSWIRE
Altimmune Announces Completion of Dosing in the Phase 2 Trial of Pemvidutide
12 Sep 2023 //
GLOBENEWSWIRE
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating Pemvidutide
01 Aug 2023 //
GLOBENEWSWIRE
Altimmune Announces Oral Presentation of Pemvidutide Data in Treatment of NAFLD
15 Jun 2023 //
GLOBENEWSWIRE
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell
11 Apr 2023 //
GLOBENEWSWIRE
